Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Support for chromosomal theory of cancer found in cancers' development of drug resistance

Support for chromosomal theory of cancer found in cancers' development of drug resistance

June 28, 2007

UC Berkeley's Peter Duesberg argues against mutation theory of cancer

Berkeley - Thirty-six years into the war on cancer, scientists have not only failed to come up with a cure, but most of the newer drugs suffer from the same problems as those available in the pre-war days: serious toxicity, limited effectiveness and eventual resistance.




This is no surprise to University of California, Berkeley, genetics researcher Peter Duesberg, professor of molecular and cell biology. According to his novel yet controversial "chromosomal" theory of cancer, which is receiving increased attention among cancer researchers, each cancer is unique, and there is no magic bullet.

"The mutation theory of cancer says that a limited number of genes causes cancer, so cancers should all be more or less the same," Duesberg said. The chromosomal theory, which he laid out in an article in the May 2007 issue of Scientific American, implies instead that, "even if cancers are from the same tissue, and are generated with the same carcinogen, they are never the same. There is always a cytogenetic and a biochemical individuality in every cancer."

The most that can be expected from a drug, he said, is that it is less toxic to normal cells than cancer cells, and that as a result a cancer detected early can be knocked back by chemotherapy. His chromosomal theory offers hope of early detection, however, since it ascribes cancer to chromosomal disruption, called aneuploidy, that can be seen easily through a microscope.

"By screening for aneuploidy, you could detect the cancer early and also see what possible drugs to use and whether drugs would even help," Duesberg noted. "Then, you wouldn't have to give a cocktail of drugs that includes all the best poisons, but you could leave out those you could tell wouldn't work. If you could cut chemotherapy drug toxicity in half or two-thirds, and direct it better at cancer, that is some progress. But it is not a cure."

Duesberg and colleagues discuss the major problem of drug resistance in cancer and how it supports the chromosomal theory of cancer in a paper appearing in the current issue of the journal Drug Resistance Updates (Vol. 10, issue 2).

Duesberg proposed in 2000 that the assumption underlying most cancer research today is wrong. That assumption, that cancer results from a handful of genetic mutations that drive a cell into uncontrolled growth, has failed to explain many aspects of cancer, he said, and has led researchers down the wrong path.

His alternative theory is that cancer results from aneuploidy - that is, duplication or sometimes loss of one or more of our 46 chromosomes, which throws thousands of genes out of whack. This condition, generated by a defect in the mechanism that duplicates chromosomes during cell growth, leads to more and more chromosomal disorder as the cells divide and proliferate, disrupting even more genes and providing ample opportunity for the development of resistance to drugs being used to control the cancer.

"In this new study and in one published in 2005, we have proved that only chromosomal rearrangements, rather than mutations, can explain the high rates and wide ranges of drug resistance in cancer cells," he said.

Duesberg even argues that the anti-leukemia drug imatinib (Gleevec®), the poster child for rational drug design once hailed as a therapy that would make drug resistance a thing of the past, has been rendered less useful because the aneuploid nature of leukemia has led to resistance. In fact, he said, this resistance suggests that imatinib is not a highly targeted drug, as advertised, but just another cell "poison" that happens to kill more leukemia cells than normal cells.

Development of drug resistance in cancer is one of the strongest arguments for the aneuploidy, or chromosomal, theory of cancer, Duesberg said, and is one aspect of cancer that can be studied experimentally. Normal cancers typically take decades to develop, making it hard to link cause and effect and to prove or disprove either the mutation or chromosomal theories. Drug resistance, however, often occurs quickly. Many cancer patients are initially heartened when their cancer starts to respond to a drug, only to find the cancer suddenly stop responding and begin to grow again.

In a paper responding to Duesberg's in the same issue of Drug Resistance Updates, Tito Fojo of the National Cancer Institute argues that there are many ways in which the mutation theory of cancer can explain drug resistance. A gene mutation, deletion, translocation or amplification could disrupt many cell functions, leading to resistance, or could inactivate or damage the doors through which a drug enters a cell.

Duesberg counters that aneuploidy is simpler and can explain the common development of resistance to many unrelated drugs within the same cancer. He has shown in experiments that aneuploidy causes many gene disruptions such as breakage or translocation each time a cancer cell divides, providing an opportunity for it to develop resistance to many drugs. Gene mutation rates in cancer cells, however, are no different from mutation rates in normal cells, making it difficult to understand how several simultaneous mutations can occur in cancer to make them resistant to more than one drug.

"The fundamental problem these conventional theories don't address is why it (drug resistance) doesn't happen in normal cells," he said. "Why aren't we all getting resistant to any toxic drug we are exposed to" Why does it happen only in cancer cells" Why do cancer cells become resistant and the patients don't""

In his experiments, Duesberg and his colleagues focus on the chromosomal fingerprint of a cell, its karyotype. For decades, physicians have known that cells of a particular cancer have the same set of marker chromosomes, a rogues gallery of normal chromosomes and stumps of chromosomes. Duesberg and UC Berkeley postdoctoral fellow Ruhong Li showed that the karyotype of drug-resistant cancer cells differs significantly from the karyotype of drug-sensitive cells from which they grew.

Clinicians have found, for example, that the gene expression profile of a breast cancer cell can tell them which treatments work best. This indicates, Duesberg said, that chromosomal disruption, which affects the expression of thousands of genes, is a better explanation for the cause of breast cancer than is the mutation theory.

"They see now, more and more, that aneuploidy cannot be ignored. It is a big elephant compared to their little mutations," he said.

Also, the more often a cancer changes karyotypes as it grows, he said, the more drugs it becomes resistant to.

"The inherent instability of aneuploidy thus explains the enormous adaptability of cancers against cytotoxic drugs and dims hopes for gene-specific therapies," Duesberg, Li and their co-authors wrote.

While this is bad news for cancer patients, Duesberg pointed out that the aneuploidy theory of cancer also provides a means for earlier detection of cancer. He and colleague David Rasnick have developed a cell scanner to search for aneuploid cells, such as from a Pap smear for cervical cancer or from biopsies for breast cancer. Rasnick formed a company to market the device, which recently was acquired by Modern Technology Corp. Aneuploid scanning is already employed in some European countries to screen for cancer.

University of California - Berkeley



Related Drug Resistance Current Events and Drug Resistance News Articles Drug Resistance Current Events and Drug Resistance News RSS Drug Resistance Current Events and Drug Resistance News RSS
Taking aim at mysterious DNA structures in the battle against cancer
Designers of anti-cancer drugs are aiming their arrows at mysterious chunks of the genetic material DNA that may play a key role in preventing the growth and spread of cancer cells, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

There's a speed limit to the pace of evolution, Penn biologists say
Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits."

Ineffective monotherapies common in high-burden malarious countries
ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk.

Paradigm shift needed to combat drug resistance
When people travel, bacteria and other infectious agents travel with them. As about a billion people cross international borders each year, many more billions of the bugs come along for the ride.

UM School of Medicine researchers find extreme genetic variability in malaria parasite
Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world.

Scientists join forces to explain HIV spread in Central and East Africa
Scientists studying biology and geography may seem worlds apart, but together they have answered a question that has defied explanation about the spread of the HIV-1 epidemic in Africa.

Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.

MUHC/McGill researchers to WHO: Time to revise tuberculosis treatment guidelines
Tuberculosis is a global threat that affects more than 10 million people each year. Working with colleagues in the United States and France, Dr. Dick Menzies of the Research Institute of the McGill University Health Centre (RI-MUHC) has placed current tuberculosis treatment guidelines under the microscope in a new study.

Man-made crises 'outrunning our ability to deal with them,' scientists warn
The world faces a compounding series of crises driven by human activity, which existing governments and institutions are increasingly powerless to cope with, a group of eminent environmental scientists and economists has warned.

New research strategy for understanding drug resistance in leukemia
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
More Drug Resistance Current Events and Drug Resistance News Articles
Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, Volume 2 (Infectious Disease)

Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, Volume 2 (Infectious Disease)
by Douglas L. Mayers (Editor)

The volumes included in Antimicrobial Drug Resistance represent the first comprehensive, multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives.

This second volume, Antimicrobial Drug Resistance, Clinical and Epidemiological Aspects, is devoted to the clinical aspects of drug resistance. Although there is evidence that restricted use of a specific antibiotic can be followed by a decrease in drug resistance to that agent, drug resistance control is not easily achieved. Thus, the infectious disease physician requires input from the clinical microbiologist and infection control specialist to make informed choices for the effective treatment of various...

Drug Abuse Resistance Education Awareness Ribbon Mouse Pad

Drug Abuse Resistance Education Awareness Ribbon Mouse Pad
by MyHeritageWear.com

The Drug Abuse Resistance Education proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Drug Abuse Resistance Education than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Drug Abuse Resistance Education mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness!

Science Magazine July 18 2008 Drug Resistance

Science Magazine July 18 2008 Drug Resistance
by Science Magazine



Dead or Alive: Final

Dead or Alive: Final
Starring: Shô Aikawa, Maria Chen, Richard Chen, Jason Chu, Josie Ho
Directed By: Takashi Miike
Also With: Ken Takeuchi (Producer), Makoto Okada (Producer), Mitsuru Kurosawa (Producer), Toshiki Kimura (Producer), Hitoshi Ishikawa (Writer), Ichiro Ryu (Writer), Yoshinobu Kamo (Writer)

The ace cop of a totalitarian police force and a drifting android play their parts in a post-apocalyptic society. They are destined to fight. Their encounter will change them forever. Studio: Kino International Release Date: 10/05/2004 Run time: 88 minutes

Antibiotic Resistance: Stopping the Superbugs

Antibiotic Resistance: Stopping the Superbugs
Directed By: ITV
Also With: ITV (Producer)



Timebomb:The Global Epidemic of Multi-Drug Resistant Tuberculosis

Timebomb:The Global Epidemic of Multi-Drug Resistant Tuberculosis
by Lee B. Reichman (Author), Janice Hopkins Tanne (Author)

"This is an excellent book. It should be read by all who are interested in any aspect of Tuberculosis, including the growing problem of Multi-Drug Resistant Tuberculosis." Journal of American Medical Association

"The book serves an important function, relaying statistics and TB hot spots, proposing funding and international standardized treatments. Government officials, researchers and nonprofit health organizations will likely cast this as the authoritative book on the subject." Publishers Weekly

"Like other recent works on the threat of infectious diseases such as Laurie Garrett's The Coming Plague, Timebomb has the power of fiction and it is sometimes easy to forget that it is not. Unlike the Garrett book, which is more a collection of short dramatic stories collectively...

PILL CONTAINER - First Aid - MEDICAL ALERT - Key Chain with Water Resistance - Large Size / Color BLACK

PILL CONTAINER - First Aid - MEDICAL ALERT - Key Chain with Water Resistance - Large Size / Color BLACK
by Changsheng Hardware



ABC Transporters and Multidrug Resistance (Wiley Series in Drug Discovery and Development)

ABC Transporters and Multidrug Resistance (Wiley Series in Drug Discovery and Development)
by Ahcène Boumendjel (Editor), Jean Boutonnat (Editor), Jacques Robert (Editor)

Wiley Series in Drug Discovery and Development

Binghe Wang, Series Editor

ABC Transporters and Multidrug Resistance

Edited by

Ahcène Boumendjel

Jean Boutonnat

Jacques Robert

A comprehensive review of the most current scientific research on ABC transporters and multidrug resistance

ATP-binding cassette transporter genes (ABC transporters) are known to play a crucial role in the development of multidrug resistance (MDR). MDR is the ability of pathologic cells, such as tumors, to withstand chemicals designed to target and destroy such cells. In MDR, patients who are on medication eventually develop resistance to not only the drug they are taking, but to several different types of drugs.

ABC Transporters and...

Amelior All-natural: Improves Mood, Joint Comfort, Stress Resistance, Complexion

Amelior All-natural: Improves Mood, Joint Comfort, Stress Resistance, Complexion
by Amelior Institute

Amelior is an all-natural nutraceutical supplement designed to alleviate serotonin receptor blockage in the brain, stimulate the bodys neurochemical system and improve bodily systems in dozens of key faculties. Amelior has been clinically proven to improve a patients mood, joint comfort, cholesterol, complexion, and much more.

Antibiotics: Actions, Origins, Resistance

Antibiotics: Actions, Origins, Resistance
by Christopher Walsh (Author)

Harvard Medical School, Boston, MA. Text analyzes how small molecules interfere selectively with the processes central to the survival of bacterial cells. Focuses on the relatively few molecules in antibiotics having an impact on human infectious disease. DNLM: Antibiotics--pharmacology.

© 2009 BrightSurf.com